{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"MAIA Biotechnology, Inc. Common Stock"},"Symbol":{"label":"Symbol","value":"MAIA"},"Address":{"label":"Address","value":"444 WEST LAKE STREET, CHICAGO, Illinois, 60606, United States"},"Phone":{"label":"Phone","value":"(872) 270-3518"},"Industry":{"label":"Industry","value":null},"Sector":{"label":"Sector","value":null},"Region":{"label":"Region","value":null},"CompanyDescription":{"label":"Company Description","value":"MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells."},"CompanyUrl":{"label":"Company Url","value":null},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Sergei M. Gryaznov","title":"Chief Scientific Officer"},{"name":"Vlad Vitoc","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}